首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1935201

抗核抗體檢測市場按產品類型、疾病、技術、最終用戶和地區分類

Anti-nuclear Antibody Testing Market, By Product Type, By Disease, By Technique, By End Users, By Geography

出版日期: 2026年01月12日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026 年抗核抗體檢測市場規模預計為 67 億美元，預計到 2033 年將達到 92 億美元，2026 年至 2033 年的複合年成長率為 14.2%。

報告覆蓋範圍		報告詳情
基準年：	2025	2026年市場規模：	67億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
預測期（2026-2033年）複合年成長率：	14.20%	2033 年的預測值：	92億美元

抗核抗體 (ANA) 檢測市場透過檢測靶向自身細胞核的抗體，輔助診斷和治療自體免疫疾病。臨床醫生利用 ANA 檢測來識別全身性紅斑性狼瘡、類風濕性關節炎和其他結締組織疾病等病症。自體免疫疾病盛行率的上升、人們對早期診斷意識的增強以及對精準診斷工具需求的不斷成長，正推動 ANA 檢測在醫院、診斷檢查室和研究實驗室中的應用。

診斷技術的進步持續推動抗核抗體（ANA）檢測市場的發展。製造商不斷提升檢測靈敏度、自動化程度和標準化水平，從而提高檢查室工作流程的準確性和效率。先進的螢光、酵素免疫分析法）和數位成像系統的應用，有助於檢查室改善結果解讀並縮短週轉時間。此外，醫療基礎設施的不斷改進、診斷服務覆蓋範圍的擴大以及對檢查室現代化改造的持續投入，也為全球市場的持續發展提供了支持。

市場動態

隨著自體免疫疾病盛行率的上升以及醫療機構對早期準確診斷的日益重視，抗核抗體 (ANA) 檢測市場持續成長。臨床醫生依靠 ANA 檢測來支持對全身性紅斑性狼瘡、類風濕性關節炎和混合性結締組織疾病等疾病的及時干預。作為第一線篩檢工具，ANA 檢測在醫院、診斷檢查室和專科診所的應用範圍不斷擴大。醫生和患者對自體免疫疾病的認知不斷提高，進一步推動了 ANA 檢測在常規診斷流程中的應用。

技術創新持續影響市場動態。診斷公司透過採用先進的螢光、酵素免疫分析法）和自動化檢測平台，不斷提高檢測的敏感度、特異性和重複性。自動化減少了人工操作，降低了結果的變異性，使檢查室能夠更有效率地處理大量檢測樣本。數位影像系統和人工智慧輔助判讀工具也提高了結果的準確性和標準化程度，增強了人們對抗核抗體（ANA）檢測結果的信心。

監管要求和不斷發展的醫療基礎設施正進一步推動市場成長。檢查室正在採用檢驗和標準化的抗核抗體（ANA）檢測方案，以滿足嚴格的品質標準。檢查室基礎設施的擴建，尤其是在新興醫療市場，有助於提高自體免疫疾病診斷的可近性。同時，對檢查室現代化和人才隊伍建設的投資也促進了ANA檢測的更廣泛應用。儘管檢測結果解讀的差異和認知度較低可能會在某些地區限制市場成長，但持續的技術創新和對自體免疫疾病診斷日益成長的需求，將繼續為ANA檢測市場創造巨大的成長機會。

本次調查的主要特點

本報告對核抗體檢測市場進行了詳細分析，以 2025 年為基準年，給出了預測期（2026-2033 年）的市場規模（十億美元）和復合年成長率（%）。
它還重點介紹了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
該研究根據以下參數對抗核抗體檢測市場的主要企業進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
本報告的研究結果將使負責人和企業經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
抗核抗體檢測市場報告涵蓋了該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過各種用於分析抗核抗體檢測市場的策略矩陣輕鬆做出決策。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 法國
- 俄羅斯
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
中東和非洲
- 南非
- 海灣合作理事會國家
- 其他中東和非洲國家

第9章競爭情勢

公司簡介
- F. Hoffmann-La Roche Ltd.
- ERBA Diagnostics
- Zeus Scientific, Inc.
- Alere Inc.
- Bio-Rad Laboratories, Inc.
- Becton Dickinson and Company
- Antibodies, Inc.
- EUROIMMUN AG
- Immuno Concepts
- Inova Diagnostics
- Thermo Fisher Scientific, Inc.
- Trinity Biotech plc.

第10章分析師建議

機會
分析師觀點
Coherent Opportunity Map

第11章調查方法

參考
調查方法

簡介目錄

Product Code: CMI4469

Anti-nuclear Antibody Testing Market is estimated to be valued at USD 6.70 Bn in 2026 and is expected to reach USD 9.2 Bn by 2033, growing at a compound annual growth rate (CAGR) of 14.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 6.70 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	14.20%	2033 Value Projection:	USD 9.2 Bn

The anti-nuclear antibody (ANA) testing market supports the diagnosis and management of autoimmune disorders by enabling the detection of antibodies that target the body's own cell nuclei. Clinicians use ANA tests to identify conditions such as systemic lupus erythematosus, rheumatoid arthritis, and other connective tissue diseases. The rising prevalence of autoimmune disorders, growing awareness of early diagnosis, and increasing demand for accurate diagnostic tools are driving the adoption of ANA testing in hospitals, diagnostic laboratories, and research institutions.

Advances in diagnostic technology continue to strengthen the ANA testing market. Manufacturers are improving assay sensitivity, automation, and standardization to enhance accuracy and efficiency in laboratory workflows. The use of advanced immunofluorescence methods, enzyme-linked immunoassays, and digital imaging systems helps laboratories improve result interpretation and shorten turnaround times. In addition, expanding healthcare infrastructure, broader access to diagnostic services, and sustained investment in laboratory modernization are supporting continued market adoption worldwide.

Market Dynamics

The anti-nuclear antibody (ANA) testing market grows as autoimmune diseases become more prevalent and healthcare providers place greater emphasis on early and accurate diagnosis. Clinicians depend on ANA testing to support timely intervention for conditions such as systemic lupus erythematosus, rheumatoid arthritis, and mixed connective tissue disorders. As a first-line screening tool, ANA testing continues to see increasing use across hospitals, diagnostic laboratories, and specialty clinics. Greater awareness among physicians and patients about autoimmune disorders further expands the integration of ANA testing into routine diagnostic workflows.

Technological advancements continue to shape market dynamics. Diagnostic companies are enhancing test sensitivity, specificity, and reproducibility by adopting advanced immunofluorescence assays, enzyme-linked immunoassays, and automated testing platforms. Automation reduces manual processes and limits variability, allowing laboratories to handle larger testing volumes more efficiently. Digital imaging systems and artificial intelligence-assisted interpretation tools also improve result accuracy and standardization, strengthening confidence in ANA test results.

Regulatory requirements and healthcare infrastructure development further influence market growth. Laboratories respond to strict quality standards by adopting validated and standardized ANA testing solutions. Expansion of laboratory infrastructure, particularly in emerging healthcare markets, improves access to autoimmune disease diagnostics. Meanwhile, investments in laboratory modernization and workforce training support broader adoption. Although variability in test interpretation and limited awareness in some regions may constrain growth, ongoing innovation and rising demand for autoimmune diagnostics continue to create strong opportunities for the ANA testing market.

Key Features of the Study

This report provides in-depth analysis of the Anti-nuclear Antibody Testing Market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Anti-nuclear Antibody Testing Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., ERBA Diagnostics, Zeus Scientific, Inc., Alere Inc., Bio-Rad Laboratories, Inc., Becton Dickinson and Company, Antibodies, Inc., EUROIMMUN AG, Immuno Concepts, Inova Diagnostics, Thermo Fisher Scientific, Inc., and Trinity Biotech plc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Anti-nuclear Antibody Testing Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Anti-nuclear Antibody Testing Market

Market Segmentation

By Product
- Reagents & Assay Kits
- Systems & Software
- Services
By Disease
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Sjogren's Syndrome
- Scleroderma
- Other Diseases
By Technique
- ELISA
- Multiplex Assay
- Immunofluorescence Assay
By End Users
- Hospitals and Clinics
- Diagnostic Laboratories
- Others
By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Hoffmann-La Roche Ltd.
- ERBA Diagnostics
- Zeus Scientific, Inc.
- Alere Inc.
- Bio-Rad Laboratories, Inc.
- Becton Dickinson and Company
- Antibodies, Inc.
- EUROIMMUN AG
- Immuno Concepts
- Inova Diagnostics
- Thermo Fisher Scientific, Inc.
- Trinity Biotech plc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Disease
- Market Snippet, By Technique
- Market Snippet, By End-Users
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market
Regulatory Scenario
Industry Trend
Merger and Acquisitions
New System Launches/Approvals

4. Global Anti-nuclear Antibody Testing Market, By Product Type, 2026-2033 (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
Reagents & Assay kits
- Introduction
- Market Size and Forecast, 2026-2033, (USD Bn)
Systems & Software
- Introduction
- Market Size and Forecast, 2026-2033, (USD Bn)
Services
- Introduction
- Market Size and Forecast, 2026-2033, (USD Bn)

5. Global Anti-nuclear Antibody Testing Market, By Disease, 2026-2033 (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, 2026-2033, (USD Bn)
Systemic Lupus Erythematosus
- Introduction
- Market Size and Forecast, 2026-2033, (USD Bn)
Sjogren's Syndrome
- Introduction
- Market Size and Forecast, 2026-2033, (USD Bn)
Scleroderma
- Introduction
- Market Size and Forecast, 2026-2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, 2026-2033, (USD Bn)

6. Global Anti-nuclear Antibody Testing Market, By Technique, 2026-2033 (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
ELISA
- Introduction
- Market Size and Forecast, 2026-2033, (USD Bn)
Multiplex Assay
- Introduction
- Market Size and Forecast, 2026-2033, (USD Bn)
Immunofluorescence Assay
- Introduction
- Market Size and Forecast, 2026-2033, (USD Bn)

7. Global Anti-nuclear Antibody Testing Market, By End-Users, 2026-2033 (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
Hospitals and Clinics
- Introduction
- Market Size and Forecast, 2026-2033, (USD Bn)
Diagnostic Laboratories
- Introduction
- Market Size and Forecast, 2026-2033, (USD Bn)
Other
- Introduction
- Market Size and Forecast, 2026-2033, (USD Bn)

8. Global Anti-nuclear Antibody Testing Market, By Region, 2026-2033 (USD Bn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
North America
- Regional Trends
- Market Size and Forecast, By Product Type, 2026-2033 (USD Bn)
- Market Size and Forecast, By Disease, 2026-2033 (USD Bn)
- Market Size and Forecast, By Technique, 2026-2033 (USD Bn)
- Market Size and Forecast, By End Users, 2026-2033 (USD Bn)
- Market Share Analysis, By Country, 2026 and 2033 (%)
  - U.S.
  - Canada
Europe
- Regional Trends
- Market Size and Forecast, By Product Type, 2026-2033 (USD Bn)
- Market Size and Forecast, By Disease, 2026-2033 (USD Bn)
- Market Size and Forecast, By Technique, 2026-2033 (USD Bn)
- Market Size and Forecast, By End Users, 2026-2033 (USD Bn)
- Market Share Analysis, By Country, 2026 and 2033 (%)
  - U.K.
  - Germany
  - France
  - Russia
  - Rest of Europe
Asia Pacific
- Regional Trends
- Market Size and Forecast, By Product Type, 2026-2033 (USD Bn)
- Market Size and Forecast, By Disease, 2026-2033 (USD Bn)
- Market Size and Forecast, By Technique, 2026-2033 (USD Bn)
- Market Size and Forecast, By End Users, 2026-2033 (USD Bn)
- Market Share Analysis, By Country, 2026 and 2033 (%)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Regional Trends
- Market Size and Forecast, By Product Type, 2026-2033 (USD Bn)
- Market Size and Forecast, By Disease, 2026-2033 (USD Bn)
- Market Size and Forecast, By Technique, 2026-2033 (USD Bn)
- Market Size and Forecast, By End Users, 2026-2033 (USD Bn)
- Market Share Analysis, By Country, 2026 and 2033 (%)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Middle East and Africa
- Regional Trends
- Market Size and Forecast, By Product Type, 2026-2033 (USD Bn)
- Market Size and Forecast, By Disease, 2026-2033 (USD Bn)
- Market Size and Forecast, By Technique, 2026-2033 (USD Bn)
- Market Size and Forecast, By End Users, 2026-2033 (USD Bn)
- Market Share Analysis, By Country, 2026 and 2033 (%)
  - South Africa
  - GCC Countries
  - Rest of the Middle East and Africa

9. Competitive Landscape

Company Profiles
- F. Hoffmann-La Roche Ltd.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Strategies
  - Recent Developments/Updates
- ERBA Diagnostics
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Strategies
  - Recent Developments/Updates
- Zeus Scientific, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Strategies
  - Recent Developments/Updates
- Alere Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Strategies
  - Recent Developments/Updates
- Bio-Rad Laboratories, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Strategies
  - Recent Developments/Updates
- Becton Dickinson and Company
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Strategies
  - Recent Developments/Updates
- Antibodies, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Strategies
  - Recent Developments/Updates
- EUROIMMUN AG
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Strategies
  - Recent Developments/Updates
- Immuno Concepts
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Strategies
  - Recent Developments/Updates
- Inova Diagnostics
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Strategies
  - Recent Developments/Updates
- Thermo Fisher Scientific, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Strategies
  - Recent Developments/Updates
- Trinity Biotech plc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Strategies
  - Recent Developments/Updates